NSCLC	Non-small cell lung cancer
EGFR	Epidermal growth factor receptor
KRAS	Kirsten rat sarcoma virus
BRAF	v-raf murine sarcoma viral oncogene homolog B1
ALK	Anaplastic lymphoma kinase
ROS1	Proto-oncogene tyrosine–protein kinase ROS
RET	Rearranged during transfection proto-oncogene
MET	Mesenchymal–epithelial transition
ERBB2	erb-b2 receptor tyrosine kinase 2
NTRK	Neurotrophic tyrosine receptor kinase
HGF	Hepatocyte growth factor
AMPK	AMP-activated protein kinase
LKB1	Liver kinase B1
GCN	Gain of copy number
FDA	U.S. Food and Drug Administration
EMA	European Medicines Agency
po	Oral
DLT	Drug limiting toxicity
b.i.d.	Twice a day
R2PD	Recommended Phase II dose
ORR	Overall response rate
PFS	Progression-free survival
DOR	Duration of response
IO	Immunotherapy
IHC	Immunohistochemistry
CEP7	Chromosome 7 centromere
ctDNA	Circulating tumor DNA
cfDNA	Circulating-free DNA
CTCs	Circulating tumor cells
FFPE	Fresh-frozen paraffin-embedded
PPA	Positive percent agreement
NPA	Negative percent agreement
OA	Overall agreement
NCCN	National Comprehensive Cancer Network
Teliso-V	Telisotuzumab vedotin